Polymorphic forms of 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyrdazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof

US9308205B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Axel Becker · Altrip, DE
• Clemens Kuehn · Darmstadt, DE
• Christoph Saal · Otzberg, DE
• Oliver Schadt · Rodenbach, DE
• Dieter Dorsch · Ober-Ramstadt, DE
• Heinz-Hermann Bokel · Darmstadt, DE
• Frank Stieber · Heidelberg, DE
• Cristina Donini · Mandello del Lario, IT

Key dates

• Filing date: Jan 29, 2015
• Grant date: Apr 12, 2016
• Expiry date: Jan 29, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or modulation of signal transduction of kinases, in particular by the inhibition of tyrosine kinases, e.g. pathophysiological conditions such as cancer.